Cellco Inc. and Haemonetics Corp. announced last week thatthey have entered into an investment and developmentagreement to determine the feasibility of combining Cellco'scellular therapy systems with Haemonetics' automated bloodprocessing systems to produce an integrated system for cellseparation, enhancement and expansion.
Haemonetics (NYSE:HAE) of Braintree, Mass., also made anundisclosed equity investment in privately held Cellco ofGermantown, Md. The agreement also allows for additionalfuture equity investments in Cellco by Haemonetics.
(c) 1997 American Health Consultants. All rights reserved.